Glioblastoma-targeted CD4+ CAR T cells mediate superior antitumor activity

Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2

Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106

HTSeq—a Python framework to work with high-throughput sequencing data

Anders, S., Pyl, P. T., & Huber, W. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btu638 · Cited by 21,464

TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions.

Kim, D., Pertea, G., Trapnell, C., Pimentel, H., Kelley, R., & Salzberg, S. L. (2013) · Genome Biology · doi:10.1186/gb-2013-14-4-r36 · Cited by 12,668

Molecular and cellular insights into T cell exhaustion

Wherry, E. J., & Kurachi, M. (2015) · Nature Reviews Immunology · doi:10.1038/nri3862 · Cited by 4,652

Wnt signalling in stem cells and cancer

Reya, T., & Clevers, H. (2005) · Nature · doi:10.1038/nature03319 · Cited by 3,666

Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia

Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565

Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509

CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients

Turtle, C. J., Hanafi, L.-A., Berger, C., Gooley, T. A., Cherian, S., Hudecek, M., Sommermeyer, D., Melville, K., Pender, B., Budiarto, T. M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85309 · Cited by 2,112

Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation

Anderson, A. C., Joller, N., & Kuchroo, V. K. (2016) · Immunity · doi:10.1016/j.immuni.2016.05.001 · Cited by 2,096

CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia

Brentjens, R. J., Davila, M. L., Riviere, I., Park, J., Wang, X., Cowell, L. G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005930 · Cited by 2,063

TGFβ biology in cancer progression and immunotherapy

Derynck, R., Turley, S. J., & Akhurst, R. J. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0403-1 · Cited by 944

Revisiting the role of CD4+ T cells in cancer immunotherapy—new insights into old paradigms

Tay, R. E., Richardson, E. K., & Toh, H. C. (2020) · Cancer Gene Therapy · doi:10.1038/s41417-020-0183-x · Cited by 844

IL15 Enhances CAR-T Cell Antitumor Activity by Reducing mTORC1 Activity and Preserving Their Stem Cell Memory Phenotype

Alizadeh, D., Wong, R. A., Yang, X., Wang, D., Pecoraro, J. R., Kuo, C.-F., Aguilar, B., Qi, Y., Ann, D. K., Starr, R., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0466 · Cited by 467

The landscape of the mesenchymal signature in brain tumours

Behnan, J., Finocchiaro, G., & Hanna, G. (2019) · Brain · doi:10.1093/brain/awz044 · Cited by 357

Differentiation and Regulation of TH Cells: A Balancing Act for Cancer Immunotherapy

Basu, A. B., Ramamoorthi, G., Albert, G. K., Gallen, C., Beyer, A., Snyder, C., Koski, G. K., Disis, M. L., Czerniecki, B. J., & Kodumudi, K. N. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.669474 · Cited by 329

A cross-talk between CAR T cell subsets and the tumor microenvironment is essential for sustained cytotoxic activity

Boulch, M., Cazaux, M., Loe-Mie, Y., Thibaut, R., Corre, B., Lemaı̂tre, F., Grandjean, C. L., Garcia, Z., & Bousso, P. (2021) · Science Immunology · doi:10.1126/sciimmunol.abd4344 · Cited by 226

Chlorotoxin-directed CAR T cells for specific and effective targeting of glioblastoma

Wang, D., Starr, R., Chang, W.-C., Aguilar, B., Alizadeh, D., Wright, S. L., Yang, X., Brito, A., Sarkissian, A., Ostberg, J. R., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw2672 · Cited by 220

CAR T‐Cell‐Based gene therapy for cancers: new perspectives, challenges, and clinical developments

Jogalekar, M. P., Rajendran, R. L., Khan, F., Dmello, C., Gangadaran, P., & Ahn, B.-C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.925985 · Cited by 214

CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy

Burger, M. C., Zhang, C., Harter, P. N., Romanski, A., Straßheimer, F., Senft, C., Tonn, T., Steinbach, J. P., & Wels, W. S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02683 · Cited by 211

CAR-T cell performance: How to improve their persistence?

López-Cantillo, G., Urueña, C., Camacho, B. A., & Ramírez-Segura, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.878209 · Cited by 207

In Vivo Generation of CAR T Cells Selectively in Human CD4+ Lymphocytes

Agarwal, S., Hanauer, J. D. S., Frank, A. M., Riechert, V., Thalheimer, F. B., & Buchholz, C. J. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.05.005 · Cited by 193

CRISPR Screening of CAR T Cells and Cancer Stem Cells Reveals Critical Dependencies for Cell-Based Therapies

Wang, D., Prager, B. C., Gimple, R. C., Aguilar, B., Alizadeh, D., Tang, H., Lv, D., Starr, R., Brito, A., Wu, Q., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1243 · Cited by 185

IFNγ Is Critical for CAR T Cell–Mediated Myeloid Activation and Induction of Endogenous Immunity

Alizadeh, D., Wong, R. A., Gholamin, S., Maker, M. S., Aftabizadeh, M., Yang, X., Pecoraro, J. R., Jeppson, J. D., Wang, D., Aguilar, B., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1661 · Cited by 189

The Era of Cytotoxic CD4 T Cells

Cenerenti, M., Saillard, M., Romero, P. J., & Jandus, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.867189 · Cited by 184

Targeting cancers through TCR-peptide/MHC interactions

He, Q., Jiang, X., Zhou, X., & Weng, J. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0812-8 · Cited by 153

Clinical investigation of CAR T cells for solid tumors: Lessons learned and future directions

Bagley, S. J., & O’Rourke, D. M. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107419 · Cited by 147

3D-organoid culture supports differentiation of human CAR+ iPSCs into highly functional CAR T cells

Wang, Z., McWilliams‐Koeppen, H. P., Reza, H., Ostberg, J. R., Chen, W., Wang, X., Huynh, C., Vyas, V., Chang, W.-C., Starr, R., et al. (2022) · Cell stem cell · doi:10.1016/j.stem.2022.02.009 · Cited by 148

Optimizing Manufacturing Protocols of Chimeric Antigen Receptor T Cells for Improved Anticancer Immunotherapy

Stock, S., Schmitt, M. W., & Sellner, L. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20246223 · Cited by 146

Tumor-intrinsic sensitivity to the pro-apoptotic effects of IFN-γ is a major determinant of CD4+ CAR T-cell antitumor activity

Boulch, M., Cazaux, M., Cuffel, A., Guérin, M. V., Garcia, Z., Alonso, R., Lemaı̂tre, F., Beer, A., Corre, B., Menger, L., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00570-7 · Cited by 143

Role of T cells in cancer immunotherapy: Opportunities and challenges

Ahmed, H., Mahmud, A. R., Siddiquee, M. F. R., Shahriar, A., Biswas, P., Shimul, M. E. K., Ahmed, S. Z., Ema, T. I., Rahman, N., Khan, M. A., et al. (2022) · Cancer Pathogenesis and Therapy · doi:10.1016/j.cpt.2022.12.002 · Cited by 148

CTLA-4 blockade induces a microglia-Th1 cell partnership that stimulates microglia phagocytosis and anti-tumor function in glioblastoma

Chen, D., Varanasi, S. K., Hara, T., Traina, K. A., Sun, M. H., McDonald, B., Farsakoglu, Y., Clanton, J., Xu, S., Garcia-Rivera, L., et al. (2023) · Immunity · doi:10.1016/j.immuni.2023.07.015 · Cited by 117

An IL-4/21 Inverted Cytokine Receptor Improving CAR-T Cell Potency in Immunosuppressive Solid-Tumor Microenvironment

Wang, Y., Jiang, H., Luo, H., Sun, Y., Shi, B., Sun, R., & Li, Z. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01691 · Cited by 112

Glioblastoma Immune Landscape and the Potential of New Immunotherapies

Daubon, T., Hémadou, A., Garmendia, I. R., & Saleh, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.585616 · Cited by 111

EZH1 repression generates mature iPSC-derived CAR T cells with enhanced antitumor activity

Jing, R., Scarfò, I., Najia, M. A. T., da Rocha, E. L., Han, A., Sanborn, M., Bingham, T., Kubaczka, C., Jha, D. K., Falchetti, M., et al. (2022) · Cell stem cell · doi:10.1016/j.stem.2022.06.014 · Cited by 96

Understanding CAR T cell-tumor interactions: Paving the way for successful clinical outcomes

Korell, F., Berger, T. R., & Maus, M. V. (2022) · Med · doi:10.1016/j.medj.2022.05.001 · Cited by 103

Strategies to enhance CAR-T persistence

Liu, Y., An, L., Huang, R., Xiong, J., Yang, H., Wang, X., & Zhang, X. (2022) · Biomarker Research · doi:10.1186/s40364-022-00434-9 · Cited by 97

GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma

Park, J. A., & Cheung, N.-K. V. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-01012-y · Cited by 88

Hypoxia Selectively Impairs CAR-T Cells In Vitro

Berahovich, R., Liu, X., Zhou, H., Tsadik, E., Xu, S., Golubovskaya, V., & Wu, L. (2019) · Cancers · doi:10.3390/cancers11050602 · Cited by 95

Determinants of response and resistance to CAR T cell therapy

Lesch, S., Benmebarek, M.-R., Cadilha, B. L., Stoiber, S., Subklewe, M. S., Endres, S., & Kobold, S. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.11.004 · Cited by 96

Engineering better chimeric antigen receptor T cells

Zhang, H., Zhao, P., & Huang, H. (2020) · Experimental Hematology & Oncology · doi:10.1186/s40164-020-00190-2 · Cited by 93

Reprogramming T cell differentiation and exhaustion in CAR-T cell therapy

Bulliard, Y., Andersson, B. S., Baysal, M. A., Damiano, J. S., & Tsimberidou, A. M. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01504-7 · Cited by 98

Universal redirection of CAR T cells against solid tumours via membrane-inserted ligands for the CAR

Zhang, A. Q., Hostetler, A., Chen, L. E., Mukkamala, V., Abraham, W. D., Padilla, L. T., Wolff, A. N., Maiorino, L., Backlund, C. M., Aung, A., et al. (2023) · Nature Biomedical Engineering · doi:10.1038/s41551-023-01048-8 · Cited by 93

Different T-cell subsets in glioblastoma multiforme and targeted immunotherapy

Wang, H., Zhou, H., Xu, J., Lu, Y., Ji, X., Yao, Y., Hou, C., Zhang, J., Zhang, X., Yao, S., et al. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.09.028 · Cited by 91

Persistent STAT5 activation reprograms the epigenetic landscape in CD4 + T cells to drive polyfunctionality and antitumor immunity

Ding, Z., Shi, H., Aboelella, N. S., Fesenkova, K., Park, E.-J., Liu, Z., Pei, L., Li, J., McIndoe, R., Xu, H., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.aba5962 · Cited by 82

CD4+ Cytotoxic T cells – Phenotype, Function and Transcriptional Networks Controlling Their Differentiation Pathways

Preglej, T., & Ellmeier, W. (2022) · Immunology Letters · doi:10.1016/j.imlet.2022.05.001 · Cited by 86

Next Generation CAR T Cells for the Immunotherapy of High-Grade Glioma

Petersen, C. T., & Krenciute, G. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00069 · Cited by 85

CD70 as an actionable immunotherapeutic target in recurrent glioblastoma and its microenvironment

Seyfrid, M., Maich, W. T., Shaikh, M. V., Tatari, N., Upreti, D., Piyasena, D., Subapanditha, M., Savage, N. J., McKenna, D., Mikolajewicz, N., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003289 · Cited by 83

Genetically Engineered T-Cells for Malignant Glioma: Overcoming the Barriers to Effective Immunotherapy

Chuntova, P., Downey, K., Hegde, B., Almeida, N. D., & Okada, H. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03062 · Cited by 71

Tumor Interferon Signaling Is Regulated by a lncRNA INCR1 Transcribed from the PD-L1 Locus

Mineo, M., Lyons, S. M., Zdioruk, M. I., von Spreckelsen, N., Ferrer-Luna, R., Ito, H., Alayo, Q. A., Kharel, P., Giantini-Larsen, A., Fan, W. Y., et al. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.05.015 · Cited by 70

Targeting senescent cells with NKG2D-CAR T cells

Deng, Y., Kumar, A., Xie, K., Schaaf, K., Scifo, E., Morsy, S., Li, T., Ehninger, A., Bano, D., & Ehninger, D. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-01976-7 · Cited by 75

Preclinical Evaluation of CAR T Cell Function: In Vitro and In Vivo Models

Si, X., Xiao, L., Brown, C. E., & Wang, D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063154 · Cited by 70

Regulation and impact of tumor-specific CD4+ T cells in cancer and immunotherapy

Guo, M., Liu, M. Y. R., & Brooks, D. G. (2024) · Trends in Immunology · doi:10.1016/j.it.2024.02.005 · Cited by 66

Investigation of the Impact from IL-2, IL-7, and IL-15 on the Growth and Signaling of Activated CD4+ T Cells

Coppola, C. D., Hopkins, B., Huhn, S. C., Du, Z., Huang, Z. J., & Kelly, W. J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21217814 · Cited by 65

CD4+ T Cells: Multitasking Cells in the Duty of Cancer Immunotherapy

Richardson, J. R., Schöllhorn, A., Gouttefangeas, C., & Schuhmacher, J. (2021) · Cancers · doi:10.3390/cancers13040596 · Cited by 66

Role and Potential of Different T Helper Cell Subsets in Adoptive Cell Therapy

Andreu-Sanz, D., & Kobold, S. (2023) · Cancers · doi:10.3390/cancers15061650 · Cited by 67

CD4 CAR-T cells targeting CD19 play a key role in exacerbating cytokine release syndrome, while maintaining long-term responses

Bove, C., Arcangeli, S., Falcone, L., Camisa, B., Khoury, R. E., Greco, B. M., Lucia, A. D., Bergamini, A., Bondanza, A., Ciceri, F., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005878 · Cited by 64

PTK7-Targeting CAR T-Cells for the Treatment of Lung Cancer and Other Malignancies

Jie, Y., Liu, G., Feng, L., Li, Y., Mingyan, E., Wu, L., Li, Y., Rong, G., Li, Y., Wei, H., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.665970 · Cited by 61

Vaccination against RhoC induces long-lasting immune responses in patients with prostate cancer: results from a phase I/II clinical trial

Schuhmacher, J., Heidu, S., Balchen, T., Richardson, J. R., Schmeltz, C., Sonne, J., Schweiker, J., Rammensee, H., Straten, P. T., Røder, M. A., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001157 · Cited by 62

Harnessing Antitumor CD4+ T Cells for Cancer Immunotherapy

Khelil, M. B., Godet, Y., Abdeljaoued, S., Borg, C., Adotévi, O., & Loyon, R. (2022) · Cancers · doi:10.3390/cancers14010260 · Cited by 63

Genetic Modification Strategies to Enhance CAR T Cell Persistence for Patients With Solid Tumors

DeRenzo, C. C., & Gottschalk, S. M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00218 · Cited by 57

CAR T cells and checkpoint inhibition for the treatment of glioblastoma

Shen, S. H., Woroniecka, K. I., Barbour, A. B., Fecci, P. E., Sanchez-Perez, L. A., & Sampson, J. H. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1727436 · Cited by 62

The outstanding antitumor capacity of CD4+ T helper lymphocytes

Li, T., Wu, B., Yang, T., Zhang, L., & Jin, K. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188439 · Cited by 60

Intratumoral pan-ErbB targeted CAR-T for head and neck squamous cell carcinoma: interim analysis of the T4 immunotherapy study

Papa, S., Adami, A. A., Metoudi, M., Beatson, R., George, M., Achkova, D., Williams, E., Arif, S., Reid, F., Elstad, M., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007162 · Cited by 58

Harnessing neoantigen specific CD4 T cells for cancer immunotherapy

Brightman, S. E., Naradikian, M. S., Miller, A. M., & Schoenberger, S. P. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.5ri0220-603rr · Cited by 57

Knowns and Unknowns about CAR-T Cell Dysfunction

Titov, A., Kaminskiy, Y., Ganeeva, I., Zmievskaya, E., Valiullina, A., Rakhmatullina, A., Petukhov, A., Рифкатовна, М. Р., Rizvanov, A. A., & Bulatov, E. (2022) · Cancers · doi:10.3390/cancers14041078 · Cited by 56

Enhancing anti-EGFRvIII CAR T cell therapy against glioblastoma with a paracrine SIRPγ-derived CD47 blocker

Martins, T. A., Kaymak, D., Tatari, N., Gerster, F., Hogan, S., Ritz, M.-F., Sabatino, V., Wieboldt, R., Bartoszek, E. M., McDaid, M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54129-w · Cited by 54

Evidence of long‐lasting anti‐CD19 activity of engrafted CD19 chimeric antigen receptor–modified T cells in a phase I study targeting pediatrics with acute lymphoblastic leukemia

Ma, F., Ho, J., Du, H., Fan, X., Wu, X., Wang, Q., Wang, L., Liu, Y., Ba, M., Wang, Y., et al. (2019) · Hematological Oncology · doi:10.1002/hon.2672 · Cited by 52

HIV-Resistant and HIV-Specific CAR-Modified CD4+ T Cells Mitigate HIV Disease Progression and Confer CD4+ T Cell Help In Vivo

Maldini, C. R., Gayout, K., Leibman, R. S., Dopkin, D. L., Mills, J. P., Shan, X., Glover, J. A., & Riley, J. L. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.05.012 · Cited by 50

Impact of the selective A2AR and A2BR dual antagonist AB928/etrumadenant on CAR T cell function

Seifert, M., Benmebarek, M.-R., Briukhovetska, D., Märkl, F., Dörr, J., Cadilha, B. L., Jobst, J., Stock, S., Andreu-Sanz, D., Lorenzini, T., et al. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-02013-z · Cited by 51

The role of CD4+ T cells in tumor and chronic viral immune responses

Xie, L., Fang, J., Yu, J., Zhang, W., He, Z., Ye, L., & Wang, H. (2023) · MedComm · doi:10.1002/mco2.390 · Cited by 54

MEK inhibition prevents CAR-T cell exhaustion and differentiation via downregulation of c-Fos and JunB

Wang, X., Xiao, T., Chen, P., Jiang, P., Li, W., Chang, H., Wei, C., Lai, X., Zhang, H., Pan, Y., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01986-y · Cited by 52

Challenges and limitations of chimeric antigen receptor T-cell therapies in solid tumors: why are approvals restricted to hematologic malignancies?

Vo, M.-C., Tran, V.-D.-H., Nguyen, V., Ruzimurodov, N., Trung, D. T., Kim, S. K., Jung, S., & Lee, J. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01744-9 · Cited by 59

Oligonucleotide Therapeutics as a New Class of Drugs for Malignant Brain Tumors: Targeting mRNAs, Regulatory RNAs, Mutations, Combinations, and Beyond

Krichevsky, A. M., & Uhlmann, E. J. (2019) · Neurotherapeutics · doi:10.1007/s13311-018-00702-3 · Cited by 48

Distinct Stromal and Immune Features Collectively Contribute to Long-Term Survival in Pancreatic Cancer

Sadozai, H., Acharjee, A., Eppenberger‐Castori, S., Gloor, B., Gruber, T., Schenk, M., & Karamitopoulou, E. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.643529 · Cited by 47

Switch receptor T3/28 improves long-term persistence and antitumor efficacy of CAR-T cells

Zhao, S., Wang, C., Lu, P., Lou, Y., Liu, H., Wang, T., Yang, S., Bao, Z., Han, L. G., Liang, X., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003176 · Cited by 46

T Cell Reprogramming Against Cancer

Katz, S. G., & Rabinovich, P. M. (2019) · Methods in molecular biology · doi:10.1007/978-1-0716-0203-4_1 · Cited by 45

Activated NK cells reprogram MDSCs via NKG2D-NKG2DL and IFN-γ to modulate antitumor T-cell response after cryo-thermal therapy

Peng, P., Lou, Y., Wang, S., Wang, J., Zhang, Z., Du, P., Zheng, J., Liu, P., & Xu, L. X. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005769 · Cited by 43

Optimization of manufacturing conditions for chimeric antigen receptor T cells to favor cells with a central memory phenotype

Gargett, T., Truong, N. T., Ebert, L. M., Yu, W., & Brown, M. P. (2019) · Cytotherapy · doi:10.1016/j.jcyt.2019.03.003 · Cited by 39

Clinical chimeric antigen receptor‐T cell therapy: a new and promising treatment modality for glioblastoma

Brown, M. P., Ebert, L. M., & Gargett, T. (2019) · Clinical & Translational Immunology · doi:10.1002/cti2.1050 · Cited by 40

Novel high‐affinity EGFRvIII‐specific chimeric antigen receptor T cells effectively eliminate human glioblastoma

Abbott, R. C., Verdon, D. J., Gracey, F. M., Hughes‐Parry, H. E., Iliopoulos, M., Watson, K. A., Mulazzani, M., Luong, K., D’Arcy, C. E., Sullivan, L. C., et al. (2021) · Clinical & Translational Immunology · doi:10.1002/cti2.1283 · Cited by 38

Epigenetic Reprogramming of CD4+ Helper T Cells as a Strategy to Improve Anticancer Immunotherapy

Renaude, E., Kroemer, M., Borg, C., Peixoto, P., Hervouet, É., Loyon, R., & Adotévi, O. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.669992 · Cited by 40

Current and Future Roles of Chimeric Antigen Receptor T-Cell Therapy in Neurology

Ismail, F. S., Gallus, M., Meuth, S. G., Okada, H., Hartung, H.-P., & Melzer, N. (2024) · JAMA Neurology · doi:10.1001/jamaneurol.2024.3818 · Cited by 41

Histone deacetylases 1 and 2 restrain CD4+ cytotoxic T lymphocyte differentiation

Preglej, T., Hamminger, P., Luu, M., Bulat, T., Andersen, L., Göschl, L., Stolz, V., Rica, R., Sandner, L., Waltenberger, D., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.133393 · Cited by 36

Predicting T‐cell quality during manufacturing through an artificial intelligence‐based integrative multiomics analytical platform

Odeh‐Couvertier, V. Y., Dwarshuis, N. J., Colonna, M. B., Levine, B. L., Edison, A. S., Kotanchek, T., Roy, K., & Torres‐García, W. (2021) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10282 · Cited by 33

Harnessing type I interferon-mediated immunity to target malignant brain tumors

Lim, J., Kang, I., La, J., Ku, K. B., Kang, B. H., Kim, Y., Park, W. H., & Lee, H. K. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1203929 · Cited by 35

Potential of Glioblastoma-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy

Salinas, R. D., Durgin, J. S., & O’Rourke, D. M. (2020) · CNS Drugs · doi:10.1007/s40263-019-00687-3 · Cited by 35

Anti-CAIX BBζ CAR4/8 T cells exhibit superior efficacy in a ccRCC mouse model

Wang, Y., Buck, A., Grimaud, M., Culhane, A. C., Kodangattil, S. R., Razimbaud, C., Bonal, D. M., Nguyen, Q., Zhu, Z., Wei, K. S., et al. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.12.019 · Cited by 34

Single-cell transcriptomics identifies multiple pathways underlying antitumor function of TCR- and CD8αβ-engineered human CD4 + T cells

Rath, J. A., Bajwa, G., Carrères, B. M., Hoyer, E. A., Gruber, I., Martinez-Paniagua, M. A., Yu, Y.-R., Nouraee, N., Sadeghi, F., Wu, M., et al. (2020) · Science Advances · doi:10.1126/sciadv.aaz7809 · Cited by 30

Pre-clinical validation of a pan-cancer CAR-T cell immunotherapy targeting nfP2X7

Bandara, V., Foeng, J., Gundsambuu, B., Norton, T. S., Nápoli, S., McPeake, D. J., Tyllis, T. S., Rad, E. R., Abbott, C. A., Mills, S. J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41338-y · Cited by 33

Contextual Reprogramming of CAR-T Cells for Treatment of HER2+ Cancers

Yang, Z., Li, L., Turkoz, A., Chen, P., Harari-Steinfeld, R., Bobbin, M. L., Stefanson, O., Choi, H., Pietrobon, V., Alphson, B., et al. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-021-03132-6 · Cited by 32

Development of HIV-Resistant CAR T Cells by CRISPR/Cas-Mediated CAR Integration into the CCR5 Locus

Rothemejer, F. H., Lauritsen, N. P., Juhl, A. K., Schleimann, M. H., König, S., Søgaard, O. S., Bak, R. O., & Tolstrup, M. (2023) · Viruses · doi:10.3390/v15010202 · Cited by 31

Genetic Abnormalities, Clonal Evolution, and Cancer Stem Cells of Brain Tumors

Testa, U., Castelli, G., & Pelosi, E. (2018) · Medical Sciences · doi:10.3390/medsci6040085 · Cited by 33

Generating allogeneic CAR-NKT cells for off-the-shelf cancer immunotherapy with genetically engineered HSP cells and feeder-free differentiation culture

Li, Y.-R., Zhou, K., Lee, D., Zhu, Y., Halladay, T., Yu, J., Zhou, Y., Lyu, Z., Fang, Y., Chen, Y., et al. (2025) · Nature Protocols · doi:10.1038/s41596-024-01077-w · Cited by 30

Targeting interleukin-13 receptor α2 (IL-13Rα2) for glioblastoma therapy with surface functionalized nanocarriers

Liang, R., Wu, C., Liu, S., & Zhao, W. (2022) · Drug Delivery · doi:10.1080/10717544.2022.2075986 · Cited by 29

EGFR as a potent CAR T target in triple negative breast cancer brain metastases

Subham, S., Jeppson, J. D., Worcester, C. R., Schatmeyer, B. A., Zhao, J., Madan, R., Lakis, N. S., Kimler, B. F., McGuirk, J. P., Chen, R. C., et al. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06783-1 · Cited by 30

Chimeric antigen receptor modified T cell (CAR-T) co-expressed with ICOSL-41BB promote CAR-T proliferation and tumor rejection

Hu, W., Huang, X., Huang, X., Chen, W., Hao, L.-D., & Chen, Z. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109333 · Cited by 28

Paving New Roads for CARs

Wittsten, A. H., & Roybal, K. T. (2019) · Trends in cancer · doi:10.1016/j.trecan.2019.09.005 · Cited by 27

c-Met specific CAR-T cells as a targeted therapy for non-small cell lung cancer cell A549

Min, J., Long, C., Zhang, L., Duan, J., Fan, H., Chu, F., & Li, Z. (2022) · Bioengineered · doi:10.1080/21655979.2022.2058149 · Cited by 28

Cell Granularity Reflects Immune Cell Function and Enables Selection of Lymphocytes with Superior Attributes for Immunotherapy

Wu, T., Tan, J. H. L., Sin, W., Luah, Y. H., Tan, S. Y., Goh, M., Birnbaum, M. E., Chen, Q., & Cheow, L. F. (2023) · Advanced Science · doi:10.1002/advs.202302175 · Cited by 29

Chimeric Antigen Receptor T Cells in Glioblastoma—Current Concepts and Promising Future

Kringel, R., Lamszus, K., & Mohme, M. (2023) · Cells · doi:10.3390/cells12131770 · Cited by 26

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

Wang, D., Starr, R., Alizadeh, D., Yang, X., Forman, S. J., & Brown, C. E. (2019) · Journal of Visualized Experiments · doi:10.3791/59275 · Cited by 27

Engineering for Success: Approaches to Improve Chimeric Antigen Receptor T Cell Therapy for Solid Tumors

Mata, M., & Gottschalk, S. M. (2019) · Drugs · doi:10.1007/s40265-019-01071-7 · Cited by 25

Enhanced Chimeric Antigen Receptor T Cell Therapy through Co-Application of Synergistic Combination Partners

Stock, S., Kluever, A.-K., Endres, S., & Kobold, S. (2022) · Biomedicines · doi:10.3390/biomedicines10020307 · Cited by 25

Charting the Course: Sequencing Immunotherapy for Multiple Myeloma

Mohan, M., Oekelen, O. V., Akhtar, O. S., Cohen, A. D., & Parekh, S. S. (2024) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_432204 · Cited by 27

Engineering resilient CAR T cells for immunosuppressive environment

Khalifeh, M., & Salman, H. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.01.035 · Cited by 25

Vaccine-based immunotherapy and related preclinical models for glioma

Yao, L., Hatami, M., Ma, W., & Skutella, T. (2024) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2024.06.009 · Cited by 28

Keeping Myeloma in Check: The Past, Present and Future of Immunotherapy in Multiple Myeloma

Ackley, J. C., Ochoa, M. A., Ghoshal, D., Roy, K., Lonial, S., & Boise, L. (2021) · Cancers · doi:10.3390/cancers13194787 · Cited by 25

Impact of Immunotherapy on CD4 T Cell Phenotypes and Function in Cancer

Saillard, M., Cenerenti, M., Romero, P., & Jandus, C. (2021) · Vaccines · doi:10.3390/vaccines9050454 · Cited by 23

Pharmacodynamic changes in tumor and immune cells drive iberdomide’s clinical mechanisms of activity in relapsed and refractory multiple myeloma

Amatangelo, M. D., Flynt, E., Stong, N., Ray, P. R., Oekelen, O. V., Wang, M., Ortiz, M., Maciag, P., Peluso, T., Parekh, S. S., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101571 · Cited by 23

Multi-Omics Analysis Reveals Novel Subtypes and Driver Genes in Glioblastoma

Yang, Y., Pan, Q., Xiang, W., Yanhui, L., Li, Y., & Mao, Q. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.565341 · Cited by 23

198. CD4+ IL13Rα2-Specific CAR T Cells Exhibit Potent Effector Function Against Glioblastoma

Wang, D., Starr, R., Aguilar, B., Brito, A., Chang, B., Sarkissian, A., Badie, B., Barish, M. E., Forman, S. J., & Brown, C. E. (2016) · Molecular Therapy · doi:10.1016/s1525-0016(16)33007-6

Abstract 3024: CD4+ outperform CD8+ central memory-derived CAR T cells, mediating persistent antitumor responses and long-term eradication of glioblastoma

Wang, D., Starr, R., Aguilar, B., Brito, A., Chang, B., Sarkissian, A., Badie, B., Barish, M. E., Forman, S. J., & Brown, C. E. (2017) · Cancer Research · doi:10.1158/1538-7445.am2017-3024

The development and potent antitumor efficacy of CD44/CD133 dual-targeting IL7Rα-armored CAR-T cells against glioblastoma

Zhai, Y., Li, G., Pan, C., Yu, M., Hu, H., Wang, D., Shi, Z., Jiang, T., & Zhang, W. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217541 · Cited by 33

P06.01 Functional analysis of IL13Rα2-specific chimeric antigen receptor T cells in immunocompetent mouse of glioblastoma

Pituch, K. C., Miska, J. M., Krenciute, G., Li, G., Panek, W. K., Gottschalk, S. M., & Balyasnikova, I. V. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox036.175

CAR T-cell therapy for glioblastoma: ready for the next round of clinical testing?

Prinzing, B. L., Gottschalk, S. M., & Krenciute, G. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1451749 · Cited by 22